Project description:Genome wide DNA methylation profiling of 4 cell populations purified from paediatic bronchoalveolar lavage samples. The cell types profiled are alveolar macrophages, granulocytes, lymphocytes and alveolar epithelial cells. Fluorescence-activated single cell sorting was used to purify the cell populations of interest using previously described methods (Shanthikumar, AJRCMB, 2020 ;63(2):152-159). Genome wide DNA methylation profiling was performed via the EPICArray. These data can be used for reference based deconvolution of cell proportion of bronchoalveolar lavage samples. DNA extracted from raw BAL (n=6) was also profiled using the EPICArray, allowing for validation of reference based deconvulution.
Project description:AJ mouse is susceptible to lung carcinogenesis from urethane treatment and is a good model for human adenocarcinoma. We completed a study using microarray analysis of bronchoalveolar lavage cells from control or urethane treated mice. A unique macrophage expression signature in the lung tumor microenvironment was able to correctly classify the lavage samples. Experiment Overall Design: RNA from bronchoalveolar lavage cells of age matched untreated AJ mice controls (C) or from urethane treated (T) AJ mice was prepared. Datasets were accurately classified using a unique macrophage gene expression signature derived from the tumor microenvironment.
Project description:AJ mouse is susceptible to lung carcinogenesis from urethane treatment and is a good model for human adenocarcinoma. We completed a study using microarray analysis of bronchoalveolar lavage cells from control or urethane treated mice. A unique macrophage expression signature in the lung tumor microenvironment was able to correctly classify the lavage samples. Keywords: AJ mouse control and urethane treatment carcinogenesis protocol
Project description:Bronchoalveolar lavage is commonly performed to examine inflammation and responsible pathogens in lung diseases, and its findings may be used to assess the immune profile of the lung tumor microenvironment (TME). To investigate whether analyses of bronchoalveolar lavage fluid (BALF) can help identify non-small cell lung cancer (NSCLC) patients who respond to immune checkpoint inhibitors (ICIs), BALF and blood were prospectively collected before initiating nivolumab. The secreted molecules, microbiome, and cellular profiles based on BALF and blood analysis were compared regarding therapeutic effect in 12 patients. Compared to non-responders, responders showed significantly higher CXCL9 levels and greater diversity in the lung microbiome profile in BALF, and greater frequency of CD56+ subset in blood T cells, whereas no significant difference was found in PD-L1 expression of tumor cells. Antibiotic treatment in a preclinical lung cancer model significantly decreased CXCL9 in the lung TME, resulting in reduced sensitivity to nivolumab, which was reversed by CXCL9 induction in tumor cells. Thus, CXCL9 and the microbiome in the lung TME might be associated with each other, and their balance could contribute to nivolumab sensitivity in NSCLC patients. BALF analysis can help predict the efficacy of ICIs when performed along with currently approved examinations.
Project description:Bronchoalveolar Lavage cells include resident and infiltrating immune cells in repsone to infections. We used single cell RNA sequencing (scRNA-seq) to analyze the diversity of BALF cells.